China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Thermo Fisher Scientific on Wednesday morning reported a 1 percent increase in fourth quarter revenues and a 22 percent rise in full-year 2021 revenues. The company also raised its revenue and earnings guidance for 2022.

Two researchers from Skoltech and McGill University have published a review of the promising research field known as structural proteomics in the influential journal Chemical Reviews.

Danaher reported on Thursday a 21 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate. For the three months ended Dec. 31, conglomerate posted $8.15 billion in total sales compared to $6.76 billion in the year-ago period. The analysts' average estimate was $7.92 billion.

iHealth announced that it was disclosed in the previous announcement that the U.S. subsidiary of the company and the ACC of U.S. signed a purchase contract on ihealth coronavirus antigen home self-test OTC kit products on behalf of HHS, purchasing a total of 250 million iHealth kit products.

VIEW has been indexed in Chemical Abstracts Service (CAS) and Information Service for the Physics, Electro-technology, Computer and Control (INSPEC).

Abbott reported Wednesday morning that its fourth quarter diagnostics revenues rose 3 percent year over year, largely as a result of rapid COVID-19 testing.

GE's healthcare systems organic revenues in the fourth quarter declined 5%, more than offsetting 2% organic growth in pharmaceutical diagnostics. Nonetheless, Culp told investors that healthcare order demand remained strong in the quarter despite supply chain disruptions.

Johnson & Johnson on Tuesday projected that its Covid vaccine would generate $3 billion to $3.5 billion in sales in 2022, after posting a mixed fourth-quarter report that slightly beat on earnings estimates but missed on revenue.

Imagine getting a positive result on a genetic test. The doctor tells you that you have a “pathogenic genetic variant,” or a DNA sequence that is known to raise the chances for getting a disease like breast cancer or diabetes.

Gene editing company Metagenomi said on Tuesday that it has raised $175 million in a Series B financing round, bringing the total funding for the Emeryville, California-based startup to $300 million.